A Phase 1b Randomized Blinded Placebo-Controlled, Cross-Over Study to Assess the Effect of AZD5634 on Mucociliary Clearance as Well as Safety, Tolerability, and Pharmacokinetic Parameters Following Single Inhaled Dose Administration to Patients With Cystic Fibrosis.
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2017
At a glance
- Drugs AZD 5634 (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 06 Sep 2017 Planned End Date changed from 17 Oct 2017 to 12 Jan 2018.
- 06 Sep 2017 Planned primary completion date changed from 17 Oct 2017 to 12 Jan 2018.
- 05 Jun 2017 Planned End Date changed from 11 Oct 2017 to 17 Oct 2017.